Prevalence and Reversibility of Lung Hyperinflation in Asthma (Dist'air2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01573364
Recruitment Status : Completed
First Posted : April 9, 2012
Last Update Posted : April 9, 2012
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

Brief Summary:
The aim of this observational study is to evaluate the pulmonary hyperinflation and its immediate reversibility to a short acting beta2 agonist test in uncontrolled persistent asthmatic patients with dyspnea.

Condition or disease

Detailed Description:

The other objectives are :

  • the evaluation of the hyperinflation defined by an increase of the residual volume (RV),
  • the observation of the relationship between the hyperinflation and the asthma characteristics,
  • the study of the improvement of the functional parameters after a reversibility test
  • the evaluation of the correlation between hyperinflation parameters evolution, chest tightness and dyspnea

Study Type : Observational
Actual Enrollment : 450 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Prevalence and the Reversibility of the Lung Hyperinflation in Uncontrolled Persistent Asthmatic Patients With Dyspnea
Study Start Date : February 2011
Actual Primary Completion Date : October 2011
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Inclusion Criteria:

  • Patient with a diagnosis of uncontrolled persistent asthma (ACT </= 19) or with an MRC score of dyspnea >/= 1
  • Patient requiring a check-up including a pulmonary function test by plethysmography with a reversibility test

Exclusion Criteria:

  • Patient participating to an other clinical trial or having participated to a clinical trial with medicine in the last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01573364

Laboratoire Chiesi S.A.
Courbevoie, France
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
Study Director: Capucine de Meynard, MD Chiesi S.A.
Study Chair: Daniel Dusser, MD, Prof Hopital Cochin Paris France

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Chiesi Farmaceutici S.p.A. Identifier: NCT01573364     History of Changes
Other Study ID Numbers: EQFST5213
First Posted: April 9, 2012    Key Record Dates
Last Update Posted: April 9, 2012
Last Verified: April 2012

Keywords provided by Chiesi Farmaceutici S.p.A.:
Distal Airways

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases